← Back to patent-cliff list
Runcaciguat
Tier C — Watch / tradeRuncaciguat
Bayer
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：sGC
Indications (approved)：Diabetic retinopathy, Chronic renal impairment, 蛋白尿, Nephropathy, End-stage renal disease, Renal impairment
Regional status
US
Phase II
2021-03-17
EU
Phase II
2021-03-17
China
Discontinued
2021-03-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Runcaciguat?
Approved indications include: Diabetic retinopathy, Chronic renal impairment, 蛋白尿, Nephropathy, End-stage renal disease, Renal impairment.
When does the Runcaciguat patent expire?
No public expiry year is available for Runcaciguat yet; this page updates once verified.
How do I get a quote for Runcaciguat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06